Off-the-shelf cancer med company Allogene Therapeutics (Nasdaq: ALLO) has been cleared to resume clinical trial work after the US regulator determined its technology was not at fault for an observed chromosomal abnormality in a patient.
Announced in October 2021, the trial hold hollowed out the firm’s stock price, as investors worried that its technology could be fatally flawed.
Despite the apparently positive outcome, shares in the company ticked downwards following the announcement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze